Table 1 Baseline characteristics of included studies
Author Year | Continent, Country | Sex | Int./cont | Mean Age(Year) | Mean BMI | Blinding | Baseline Vit.D Status | Vitamin D dose | Study Duration (week) | Outcomesa |
|---|---|---|---|---|---|---|---|---|---|---|
Shaseb et al. 2016 [40] | Asia, Iran | both | 55/57 | 54.90 | 27.2 | Double Blind | Sufficient | 300,000, Once | 8 | 1&2 |
Farrokhian et al. 2017 [41] | Asia, Iran | both | 3030 | 61.70 | 30.2 | Double Blind | Deficient | 50,000 /w | 24 | 1&3 |
Kampman et al. 2014 [69] | Europe, Denmark | both | 8/8 | 61.60 | 33.8 | Double Blind | Deficient | 5,600/d | 12 | 1 |
Gulseth et al. 2017 [23] | Europe, Norway | both | 33/29 | 55.50 | 31.8 | Double Blind | Deficient | 400,000, Once | 24 | 1&2 |
Khan et al. 2018 [42] | Asia, Pakistan | both | 70/70 | 54.80 | NR | NR | Deficient | 50,000/w | 12 | 2 |
Ghavamzadeh et al. 2014 [43] | Asia, Iran | both | 26/25 | 52.26 | 28.9 | Double Blind | Deficient | 400/d | 14 | 2 |
Sadiya et al. 2015 [44] | Asia, UAE | both | 43/39 | 49.00 | 37.9 | Double Blind | Deficient | 6,000/d | 24 | 1&2 |
Dalan et al. 2016 [45] | Asia, Singapore | both | 31/30 | 52.20 | 27.3 | Double Blind | Deficient | 4,000/d | 16 | 2 |
Witham et al. 2010 [70] | Europe, UK | both | 19/21 | 65.30 | 31.1 | Double Blind | Deficient | 100,000, Once | 16 | 2&3 |
Witham et al. 2010 [70] | Europe, UK | both | 18/21 | 66.70 | 33.3 | Double Blind | Deficient | 200,000, Once | 16 | 2&3 |
Barchetta et al. 2016 [88] | Europe, Italy | both | 29/26 | 57.40 | 29.3 | Double Blind | Deficient | 2,000/d | 24 | 1&2&3 |
Momeni et al. 2017 [46] | Asia, Iran | both | 29/28 | 62.60 | NR | Double Blind | Deficient | 50,000/w | 8 | 1&2 |
Angellotti et al. 2018 [75] | America, USA | both | 61/59 | 60.20 | 30.9 | Double Blind | Insufficient | 4,000/d | 48 | 2 |
Omidian et al. 2019 [47] | Asia, Iran | both | 32/34 | 50.50 | 27.4 | Double Blind | Deficient | 4,000/d | 12 | 1&2 |
Rad et al. 2014 [89] | Asia, Iran | both | 30/26 | 50.00 | 28.8 | Double Blind | Deficient | 4,000/d | 8 | 1&2&3 |
Eftekhari et al. 2011 [49] | Asia, Iran | both | 35/35 | 53.80 | 28.3 | Double Blind | Sufficient | 20/d | 12 | 1&2&3 |
Ryu et al. 2014 [50] | Asia, Korea | both | 64/65 | 54.50 | 24.4 | Double Blind | Deficient | 2,000/d | 24 | 1&2&3 |
Agarwal et al. 2017 [51] | Asia, India | both | 30/30 | 55.50 | NR | Open labeled | Deficient | 60,000/2w | 12 | 1&2 |
Heshmat et al. 2012 [52] | Asia, Iran | both | 21/21 | 56.20 | 27.7 | Double Blind | Sufficient | 300,000, Once | 12 | 1&2&3 |
Soric et al. 2012 [76] | America, USA | both | 19/18 | 55.50 | NR | Single Blinding | NR | 2,000/d | 12 | 1&2 |
Shaheen et al. 2019 [53] | Asia, Pakistan | both | 70/70 | 56.60 | NR | NR | Deficient | 50,000/w | 12 | 2 |
Sugden et al. 2008 [72] | Europe, UK | both | 17/17 | 64.90 | 31.7 | Double Blind | Deficient | 100,000, Once | 8 | 2 |
Safarpour et al. 2020 [24] | Asia, Iran | both | 42/43 | 50.10 | 30.9 | Double Blind | Deficient | 50,000/w | 12 | 1&2&3 |
Upreti et al. 2018 [54] | Asia, India | both | 30/30 | 49.10 | 25.1 | Double Blind | Insufficient | 60,000/w | 24 | 1&2 |
Dadrass et al. 2019 [55] | Asia, Iran | Male | 12/12 | 53.86 | 28.1 | Double Blind | Deficient | 50,000/2w | 12 | 1&2&3 |
Baziar et al. 2014 [25] | Asia, Iran | both | 41/40 | 51.30 | 27.3 | Double Blind | Deficient | 50,000/w | 8 | 1&3 |
Krul-Poel et al. 2015 [27] | Europe, Netherland | both | 129/132 | 67.00 | 28.6 | Double Blind | Insufficient | 50,000/Month | 24 | 1&2&3 |
Jehle et al. 2014 [73] | Europe, Switzerland | both | 29/26 | 66.80 | 28.5 | Double Blind | Deficient | 300,000/double | 24 | 2&3 |
Nasri et al. 2014 [57] | Asia, Iran | both | 30/30 | 55.00 | NR | Double Blind | Sufficient | 50,000/w | 12 | 2 |
Breslavsky et al. 2013 [58] | Asia, Israel | both | 24/23 | 66.30 | 29.3 | Double Blind | Deficient | 1,000/d | 12 | 1&2&3 |
El Hajj et al. 2020 [59] | Asia, Lebanon | both | 45/43 | 66.90 | 22.7 | Double Blind | Deficient | 30,000/w | 24 | 1&2&3 |
Mirzavandi et al. 2020 [60] | Asia, Iran | both | 25/25 | 29.90 | 29.9 | Double Blind | Deficient | 200,000/double | 8 | 1 |
Imanparasta et al. 2020 [61] | Asia, Iran | both | 23/23 | 53.20 | 28.3 | Double Blind | Insufficient | 50,000/w | 16 | 1&2&3 |
Elkassaby et al. 2014 [26] | Australia, Australia | both | 26/24 | 52.00 | 30.9 | Double Blind | Insufficient | 6,000/d | 24 | 1&2&3 |
Razzaghi et al. 2017 [62] | Asia, Iran | both | 30/30 | 59.10 | 26.1 | Double Blind | Deficient | 50,000/2w | 12 | 1&2 |
Parekh et al. 2010 [63] | Asia, India | both | 14/13 | 43.72 | 23.6 | Double Blind | Deficient | 300,000, Once | 4 | 1&2 |
Al-Sofiani et al. 2015 [64] | Asia, Saudi | both | 10/10 | 54.80 | 31.2 | Double Blind | Deficient | 5,000/d | 12 | 1&2&3 |
Anyanwu et al. 2017 [78] | Africa, Nigeria | both | 17/16 | 51.80 | NR | Single Blinding | Deficient | 3,000/d | 12 | 1&2 |
Lo et al. 2019 [77] | America, USA | both | 14/16 | 58.10 | 38.6 | Double Blind | Deficient | 50,000/w | 24 | 2 |
Muley et al. 2019 [65] | Asia, India | both | 40/30 | 54.00 | 29.2 | NR | Deficient | 60,000/w | 8 | 2 |
Jorde et al. 2009 [74] | Europe, Norway | both | 16/16 | 56.25 | 32.1 | NR | Insufficient | 40,000/w | 24 | 1&2 |
Punthakee et al. 2012 [37] | 33 country | both | 607/614 | 67.00 | 30.7 | Double Blind | NR | 1,000/d | 18 | 1&2 |
Kim et al. 2014 [66] | Asia, Korea | Female | 11/13 | 72.20 | 23.9 | Double Blind | Deficient | 1,200/d | 12 | 1&3 |
Almoushawah et al 2014 [90] | Asia, Saudi | both | 91/92 | 54.70 | 31.7 | Double Blind | Deficient | 45,000/w | 12 | 1&2 |
Bhosle et al. 2018 [68] | Asia, India | both | 60/60 | NR | NR | Double Blind | Deficient | 60,000/w | 24 | 1&2 |
Shahriari et al. 2018 [39] | Asia, Iran | both | 28/29 | 58.50 | 28.0 | Double Blind | Deficient | 50,000/w | 8 | 1&2 |